FindTrial
Sign In

Serum Galectin-3 in AF

Therapeutic Implication of Galectin-3 in Patients with Atrial Fibrillation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0005496
Enrollment
75
Registered
2020-10-15
Start date
2017-02-08
Completion date
Unknown
Last updated
2020-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Korea University Anam Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Admission for catheter ablation of atrial fibrillation 2) Cardiac magnetic resonance imaging with gadolinium before ablation 3) No history of vascular or malignancy disease affecting the level of serum galectin-3

Exclusion criteria

Exclusion criteria: 1) refuse enrollment

Design outcomes

Primary

MeasureTime frame
Time to recurrence of atrial fibrillation or atrial tachycardia after ablation—

Secondary

MeasureTime frame
Time to recurrence of atrial fibrillation after ablation;Time to recurrence of atrial tachycardia after ablation;Comparisons between serum galectin-3 level and other parameters related with cardiac remodeling—

Countries

Korea, Republic of

Contacts

Public ContactKwnag-No Lee

Ajou University Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026